A5015152832- Sarcoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Angiogenesis and VEGF in Cancer
- Vascular Tumors and Angiosarcomas
- Cancer Genomics and Diagnostics
- Extracellular vesicles in disease
- Genetic factors in colorectal cancer
- Genomics and Rare Diseases
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- DNA Repair Mechanisms
- Breast Cancer Treatment Studies
- MicroRNA in disease regulation
- RNA Interference and Gene Delivery
- Pancreatic and Hepatic Oncology Research
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Metastasis and carcinoma case studies
- Viral Infections and Vectors
- Ferroptosis and cancer prognosis
Fundación Instituto Valenciano de Oncología
2019-2024
Abstract Background Because of their specific and biologically relevant cargo, urine extracellular vesicles (EVs) constitute a valuable source potential non-invasive biomarkers that could support the clinical decision-making to improve management prostate cancer (PCa) patients. Different EV isolation methods differ in terms complexity yield, conditioning, as consequence, analytical result. Methods The aim this study was compare three different for EVs: ultracentrifugation (UC), size...
Approximately 5 to 10% of all cancers are caused by inherited germline mutations, many which associated with different Hereditary Cancer Syndromes (HCS). In the context Program Valencia Community, individuals belonging specific HCS and their families receive genetic counselling testing according internationally established guidelines. The current diagnostic approach is based on sequencing a few high-risk genes related each HCS; however, this method time-consuming, expensive does not achieve...
MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level, and they have been described as being associated with tumor prognosis. Here, miRNA profiling was planned to explore new molecular prognostic biomarkers in localized intestinal high-risk GIST. Paraffin blocks of 14 86 patients were used discovery expansion sets, respectively. GeneChip v3.0 employed identify miRNAs differentially expressed between relapsed non-relapsed...
Genomic Instability (GI) is a transversal phenomenon shared by several tumor types that provide both prognostic and predictive information. In the context of high-grade serous ovarian cancer (HGSOC), response to DNA-damaging agents such as platinum-based poly(ADP-ribose) polymerase inhibitors (PARPi) has been closely linked deficiencies in DNA repair machinery homologous recombination (HRR) GI. this study, we have developed Scarface score, an integrative algorithm based on genomic...
681 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by its immunologically cold tumor microenvironment (TME) with scarce T cell infiltration and few molecular signatures of immune activation. To date, the immunotherapies including checkpoint blockade PD-1, CTLA-4 either single or in combination have shown modest results PDAC tumors. Recently, Lymphocyte Activation Gene (LAG3) has emerged as a promising target indicated preclinical clinical data. The aim this study to...
Purpose: The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of soft-tissue sarcoma cohort enrolled this trial. Experimental Design: Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline week 13. used for transcriptomics multiplex immunofluorescence, whereas multiplexed immunoassays. Flow cytometry Luminex assays performed to validate...
In recent years, liquid biopsy has emerged as a promising tool for the diagnosis and prognosis of numerous diseases, including cancer. Among biomolecules analyzed in biopsies are plasma circulating microRNAs (miRNAs), small non-coding RNAs that have proven to be crucial regulation gene expression pathobiology different health conditions, making them useful biomarkers. However, variations preanalytical conditions during biospecimen collection processing can affect analytical results.
<div>Purpose:<p>The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of soft-tissue sarcoma cohort enrolled this trial.</p>Experimental Design:<p>Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline week 13. Formalin-fixed used for transcriptomics multiplex immunofluorescence, whereas multiplexed immunoassays. Flow...
<p>Supplementary Figure S2. Correlation between progression-free survival (PFS) and the dynamic increase in cytologic markers. A) CD3; B) CD4; C) CD8; D) CD20; E) CD66b; F) CD68 G) CD138. PFS cut-off was defined as 9.4 months calculated by MAXSTAT. Significance p<0.05 Wilcoxon paired test.</p>
<p>Supplementary Figure S4. Correlation between progression-free survival (PFS) and the dynamic alteration in expression of additional soluble proteins plasma samples. Samples were collected at baseline week 13 (Cycle 3, day 1). PFS cut-off was defined as 7.2 months calculated by MAXSTAT. Significance p<0.05 Wilcoxon paired test. Concentration is represented log2 (pg/mL).</p>
<p>Supplementary Figure S5. CXCL10 protein expression in cell culture supernatant. The levels of soluble were measured after anti-CD3/CD28 stimulation and anti-PD-1 treatment PBMC cultures (A) tumor multi-cultures (B). Significance was defined as p<0.05 (Students t-test).</p>
<p>Supplementary Figure S1. Consort diagram. Number of samples included in the correlative studies HTG transcriptomics, multiplexed immunoassays and immune-phenotyping.</p>
<p>Supplementary Figure S3. Dynamic modulation of soluble factors in paired plasma samples. Samples were collected at baseline and week 13 (Cycle 3, day 1). Significance was defined as p<0.05 calculated by Wilcoxon test. Concentration is represented log2 (pg/mL).</p>
11067 Background: GEIS 30 was a phase II study showing moderate activity of pazopanib in well-differentiated/dedifferentiated LPS (cohort A:37 pts, Progression free Survival (PFS) at 12 weeks (w) 43.2%) and no Myxoid/round cell B: 15 PFS 12w 13.3%). The present aims to identify tumor plasma biomarkers that are differently expressed long responders (LRs) > 24 w. Methods: Serum samples paraffin-blocks diagnosis were collected for 28 pts cohort A 11 B. total 13 LRs. obtained baseline, after...
558 Background: Genomic platforms, such as Mammaprint (Agendia) (MP) and OncoType (Genomic Health) (OT), have been validated to determine the risk of relapse in therapeutic decision-making early-stage hormone receptor positive (HR+), epidermal growth factor 2 (HER2) negative breast cancer (BC). Discordances allocation between these platforms affect up 30% patients. This study aims develop MamaPred test improve diagnostic performance recurrence HR+/HER2- BC. Methods: A total 606 BC previously...
Abstract Background Because of their specific and biologically relevant cargo, urine extracellular vesicles (EVs) constitute a valuable source potential non-invasive biomarkers that could support the clinical decision-making to improve management prostate cancer (PCa) patients. Different EV isolation methods differ in terms complexity yield, conditioning, as consequence, analytical result. Methods The aim this study was compare three different for EVs: ultracentrifugation (UC), size...